
Opinion|Videos|November 4, 2024
Community Oncologist Perspective: Protocol Development for Bispecific Administration and AE Management
Dr Graff discusses how they developed protocols for administering bispecific antibodies and monitoring and managing associated adverse events.
Advertisement
Video content above is prompted by the following:
How did you develop your administration and adverse event monitoring and management protocols?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at SABCS 2025
2
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
3
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
4
Off-the-Shelf In Vivo BCMA CAR T KLN-1010 Yields Deep R/R Myeloma Responses
5






































